Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2002
12/05/2002WO2002053756A3 Regulation of human glucosamine-6-phosphate deaminase
12/05/2002WO2002053749A3 Regulation of human serine-threonine protein kinase
12/05/2002WO2002051866A3 Antibacterial treatments
12/05/2002WO2002051863A3 Polypeptides having a triggering nk activity and biological applications
12/05/2002WO2002048384A3 Nucleic acid sequence 'm73791' serving as a human gene, and derivatives thereof
12/05/2002WO2002047728A3 Treatment of posterior capsule opacification
12/05/2002WO2002046221A3 Human protein differentially expressed in alzheimer's disease's brain
12/05/2002WO2002043572A3 Erythropoietin and erythropoietin receptor expression in human cancer
12/05/2002WO2002042327A3 Cocoa albumin and its use in the production of cocoa and chocolate flavour
12/05/2002WO2002042321A3 Mixed fibrils
12/05/2002WO2002033097A3 Regulation of human sulfotransferase
12/05/2002WO2002031126A3 Regulation of human cyclophilin-type peptidyl-prolyl cis-trans isomerase
12/05/2002WO2002028902A3 Nectin polypeptides, polynucleotides, methods of making and use thereof
12/05/2002WO2002020766A3 G-csf analog compositions and methods
12/05/2002WO2002016413A3 Cripto tumour polypeptide
12/05/2002WO2002013862A3 Method and composition for altering a b cell mediated pathology
12/05/2002WO2002013861A3 Method and composition for altering a t cell mediated pathology
12/05/2002WO2002009685A1 Preparation with vascular protective and anti-oxidative effect and use thereof
12/05/2002WO2002006453A3 Regulation of human desc1-like serine protease
12/05/2002WO2001098362A3 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/05/2002WO2001097608A3 Cyk-4 polypeptides, dna molecules encoding them and their use in screening methods
12/05/2002WO2001096391A3 55p4h4: gene expressed in various cancers
12/05/2002WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis
12/05/2002WO2001090142A3 FULL LENGTH HUMAN HCN1 Ih CHANNEL SUBUNIT AND VARIANTS
12/05/2002WO2001088180A3 Tnf and ifn stimulated genes and uses therefor
12/05/2002WO2001088085A3 Novel bee venom polypeptides and methods of use thereof
12/05/2002WO2001085947A3 Compounds and methods for the diagnosis and treatment of babesia microti infection
12/05/2002WO2001083518A9 Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same
12/05/2002WO2001064949B1 Diagnostics and therapeutics for glaucoma
12/05/2002WO2001062928A3 Polypeptides and nucleic acids encoding same
12/05/2002WO2001060397A9 Uses of agonists and antagonists to modulate activity of tnf-related molecules
12/05/2002WO2001053456A9 Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
12/05/2002WO2001049743A9 Methods of modulation of the immune system
12/05/2002WO2001045577A9 Intervertebral disc treatment devices and methods
12/05/2002WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
12/05/2002WO2001023589A9 23431, a novel human ubiquitin protease
12/05/2002WO2001021796A9 Gl50 molecules and uses therefor
12/05/2002US20020184658 Aromatic amino acid biosynthetic enzymes
12/05/2002US20020183808 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant
12/05/2002US20020183512 Compounds for use in treatment of cancer
12/05/2002US20020183508 Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
12/05/2002US20020183507 Novel human GABA receptor proteins and polynucleotides encoding the same
12/05/2002US20020183505 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/05/2002US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002US20020183501 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of mammary gland cancer
12/05/2002US20020183500 Nucleotide sequence coding polypeptide for use in the treatment, diagnosis, classification and imaging of lung cancer
12/05/2002US20020183496 Human thymosin beta15 gene, protein and uses thereof
12/05/2002US20020183494 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/05/2002US20020183493 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/05/2002US20020183492 Isolation of biopolymers from human serum albumin; obtain human serum albumin, expose to ion exchange resin, elute and recover biopolymer
12/05/2002US20020183485 Nucleotide sequences coding receptor protein for use in the treatment of hypertriglyceridaemia, inflammation, cachexia, infections and tumors
12/05/2002US20020183396 Local anesthetic methods and kits
12/05/2002US20020183385 Administering a therapeutically effective amount of arsenic compounds to a mammal for treating solid tumor
12/05/2002US20020183369 For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis
12/05/2002US20020183356 Local anesthetic methods and kits
12/05/2002US20020183318 Novel derivatives of flavones, xanthones and coumarins
12/05/2002US20020183313 Cholecystokinin-A and B (CCK-A/B) antagonists and useful in therapy and prophylaxis of disorders of appetite regulatory systems (e.g., anorexia) disorders associated with intestinal smooth muscle hyperactivity (e.g., irritable bowel syndrome)
12/05/2002US20020183288 Administering to a subject suffering from hyperparathyroidism an amount of active vitamin D formula sufficient to lower or maintain lowered blood parathyroid hormone (PTH) levels
12/05/2002US20020183280 For controlled administration of pharmaceutically active agents to patients, wherein formulation is administered as liquids which thicken to form gels upon instillation into the eye
12/05/2002US20020183276 Administering alkaline phosphatase (TNAP) inhibitor to the tissue or patient effective to inhibit TNAP expression or activity for decreasing matrix mineralization in a tissue
12/05/2002US20020183273 Compositions and methods for improving kidney function
12/05/2002US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient
12/05/2002US20020183270 For therapy of cancer and for diagnosing tumorigenicity and other diseases
12/05/2002US20020183269 Novel compounds
12/05/2002US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002US20020183261 Oral administration of these can stimulate proliferation of osteoblast, inhibit bone resorption and strengthen bone; can be useful for improvement of osteoporosis, bone fracture, bone pain, etc
12/05/2002US20020183260 For therapy of cardiovascular disorders in mammals; for inhibiting both angiotensin converting enzyme and neutral endopeptidase in mammals
12/05/2002US20020183258 Process of inhibiting cell death in injured cartilage
12/05/2002US20020183256 Cytostatic-integrin conjugates having specifically cleavable linking units
12/05/2002US20020183255 Use of KPV tripeptide for dermatological disorders
12/05/2002US20020183254 For inhibiting blood coagulation
12/05/2002US20020183253 Effecting an increase in the amount of an endostatin in ocular tissues of an individual afflicted with ocular neovascularization to an ocular neovascularization inhibiting effective amount
12/05/2002US20020183252 To inhibit tumor growth in an animal; to induce apoptosis
12/05/2002US20020183251 For use as vaccines, and other drugs for the diagnosis and therapy of prostate cancer
12/05/2002US20020183250 For use in therapy of sleep disorders
12/05/2002US20020183249 Method of identifying inhibitors of CDC25
12/05/2002US20020183248 Locally administering to a cutaneous site at least one lectin capable of interfering with the infective capability of a pathogenic microorganism toward dermal tissue, in an amount effective to diminish infective capability microorganism
12/05/2002US20020183245 For therapy of Porphyromonas (Bacteroides) gingivalis; periodontal disorder
12/05/2002US20020183244 Coating endoluminal surface of a tissue by coating with water soluble proteinaceous material and with di- or polyaldehyde; allowing formulation to cure
12/05/2002US20020183242 Peptide antiangiogenic drugs
12/05/2002US20020182750 Intravascular apparatus method
12/05/2002US20020182729 Proliferation of neuronal cells; obtain stem cels, incubate with antagonist of pitutary adenylate cyclase activating polypeptide, moitor proliferation of neuronal cells
12/05/2002US20020182728 Method for transdifferentiation of non pancreatic stem cells to the pancreatic differentiation pathway
12/05/2002US20020182726 Calcium-independent negative regulation by CD81 of receptor signalling
12/05/2002US20020182725 New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/05/2002US20020182706 Purification of viral envelope proteins; obtain cell, transfect with genetically engineered virus, lyse cell, recover envelope proteins
12/05/2002US20020182705 Method for increasing the serum half-life of a biologically active molecule
12/05/2002US20020182703 Human defensin polypeptide Def-X, genomic DNA and cDNA, composition containing them and applications to diagnosis and to therapeutic treatment
12/05/2002US20020182702 Nuc,leotide equences coding polypeptide for use in the treatment of cancer and immunological disorders
12/05/2002US20020182701 Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
12/05/2002US20020182698 Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
12/05/2002US20020182696 Stabilized enzyme compositions
12/05/2002US20020182695 Stabilised enzyme compositions
12/05/2002US20020182684 Nucleotide sequences coding polypeptide for use in the treatment of blood disorders
12/05/2002US20020182683 Vascular endothelial growth factor 2
12/05/2002US20020182681 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
12/05/2002US20020182678 CD29 pig protein, nucleic acid coding for said protein, and applications thereof
12/05/2002US20020182676 Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia
12/05/2002US20020182671 Polypeptide for use in the treatment, diagnosis, and prevention of cell proliferative, autoimmune/inflammatory, neurological and gatrointestinal disorders
12/05/2002US20020182670 Modified factor VIII
1 ... 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 ... 3163